SG11201901374WA - Antibiotic compounds - Google Patents
Antibiotic compoundsInfo
- Publication number
- SG11201901374WA SG11201901374WA SG11201901374WA SG11201901374WA SG11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compounds
- merrifield
- lane
- centre
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000003115 biocidal effect Effects 0.000 title abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 244000178231 Rosmarinus officinalis Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 abstract 1
- 244000028344 Primula vulgaris Species 0.000 abstract 1
- 235000016311 Primula vulgaris Nutrition 0.000 abstract 1
- 241001529742 Rosmarinus Species 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614314.1A GB201614314D0 (en) | 2016-08-22 | 2016-08-22 | Antibiotic compounds |
| PCT/GB2017/052478 WO2018037223A1 (en) | 2016-08-22 | 2017-08-22 | Antibiotic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901374WA true SG11201901374WA (en) | 2019-03-28 |
Family
ID=57045563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901374WA SG11201901374WA (en) | 2016-08-22 | 2017-08-22 | Antibiotic compounds |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190194179A1 (https=) |
| EP (1) | EP3500567A1 (https=) |
| JP (1) | JP2019528291A (https=) |
| KR (1) | KR20190046894A (https=) |
| CN (1) | CN109923111A (https=) |
| AU (1) | AU2017316742A1 (https=) |
| BR (1) | BR112019003427A2 (https=) |
| CA (1) | CA3034000A1 (https=) |
| CO (1) | CO2019002624A2 (https=) |
| EA (1) | EA201990551A1 (https=) |
| GB (1) | GB201614314D0 (https=) |
| MX (1) | MX2019001978A (https=) |
| PH (1) | PH12019500360A1 (https=) |
| SG (1) | SG11201901374WA (https=) |
| WO (1) | WO2018037223A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7503051B2 (ja) | 2018-10-11 | 2024-06-19 | バイエル・アクチエンゲゼルシヤフト | イミダゾール誘導体の製造方法 |
| EP3636645A1 (de) | 2018-10-11 | 2020-04-15 | Bayer Aktiengesellschaft | Verfahren zur herstellung schwefel-substituierter pyridinderivate |
| TWI841671B (zh) | 2019-01-24 | 2024-05-11 | 日商第一三共股份有限公司 | 具有取代基之脲化合物 |
| US20220125763A1 (en) | 2019-02-22 | 2022-04-28 | Anifera Limited | Compositions providing enhanced antibacterial activity against gram-positive bacteria and use thereof |
| CN111808093B (zh) * | 2019-04-12 | 2023-05-16 | 中国医学科学院医药生物技术研究所 | 一种新德里金属-β-内酰胺酶-1抑制剂 |
| WO2020210339A1 (en) | 2019-04-12 | 2020-10-15 | Mitobridge, Inc. | Hmox1 inducers |
| US12528798B2 (en) | 2019-10-29 | 2026-01-20 | Lg Chem, Ltd. | Compound for crop protectant |
| WO2022108354A1 (ko) * | 2020-11-19 | 2022-05-27 | 주식회사 에이엔제이사이언스 | 신규 화합물, 이의 제조방법 및 이를 포함하는 항생제 조성물 |
| CN113185475A (zh) * | 2021-04-29 | 2021-07-30 | 江苏永凯化学有限公司 | 一种高效低污染的精恶唑禾草灵生产工艺 |
| CN117043141A (zh) * | 2021-05-31 | 2023-11-10 | 江苏亚虹医药科技股份有限公司 | 7-硝基-8-羟基喹啉衍生物、其制备方法及其医药用途 |
| KR102754999B1 (ko) * | 2022-01-06 | 2025-01-21 | 충남대학교산학협력단 | 신규한 화합물 및 이를 포함하는 결핵균 또는 비결핵항산균 감염질환 치료용 약제학적 조성물 |
| WO2023234970A1 (en) * | 2022-06-01 | 2023-12-07 | KUDA Therapeutics, Inc. | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of hif-1/2a pathway inhibition, and induction of ferroptosis |
| WO2024130173A1 (en) * | 2022-12-16 | 2024-06-20 | Immvention Therapeutix | Benzimidazole derivatives |
| KR102840252B1 (ko) * | 2023-04-27 | 2025-07-30 | 한국화학연구원 | 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| CN117003710A (zh) * | 2023-07-19 | 2023-11-07 | 镇江先锋植保科技有限公司 | 一种2-巯基-6-氯苯并恶唑的制备方法 |
| CN121889378A (zh) * | 2023-09-01 | 2026-04-17 | 英孚欣治疗生物技术公司 | 取代的苯并噁唑基氨基苯并噁唑 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604217B2 (en) * | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| JP5786402B2 (ja) * | 2011-03-29 | 2015-09-30 | コニカミノルタ株式会社 | 光学フィルム、及びそれを用いた偏光板、液晶表示装置 |
| WO2016039939A1 (en) * | 2014-09-09 | 2016-03-17 | Ptc Therapeutics, Inc. | Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds |
-
2016
- 2016-08-22 GB GBGB1614314.1A patent/GB201614314D0/en not_active Ceased
-
2017
- 2017-08-22 KR KR1020197008269A patent/KR20190046894A/ko not_active Withdrawn
- 2017-08-22 MX MX2019001978A patent/MX2019001978A/es unknown
- 2017-08-22 JP JP2019510688A patent/JP2019528291A/ja not_active Withdrawn
- 2017-08-22 CA CA3034000A patent/CA3034000A1/en not_active Abandoned
- 2017-08-22 BR BR112019003427-7A patent/BR112019003427A2/pt not_active Application Discontinuation
- 2017-08-22 CN CN201780063473.8A patent/CN109923111A/zh active Pending
- 2017-08-22 EP EP17761308.0A patent/EP3500567A1/en not_active Withdrawn
- 2017-08-22 AU AU2017316742A patent/AU2017316742A1/en not_active Withdrawn
- 2017-08-22 EA EA201990551A patent/EA201990551A1/ru unknown
- 2017-08-22 SG SG11201901374WA patent/SG11201901374WA/en unknown
- 2017-08-22 US US16/327,286 patent/US20190194179A1/en not_active Abandoned
- 2017-08-22 WO PCT/GB2017/052478 patent/WO2018037223A1/en not_active Ceased
-
2019
- 2019-02-20 PH PH12019500360A patent/PH12019500360A1/en unknown
- 2019-03-21 CO CONC2019/0002624A patent/CO2019002624A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018037223A1 (en) | 2018-03-01 |
| CA3034000A1 (en) | 2018-03-01 |
| EP3500567A1 (en) | 2019-06-26 |
| AU2017316742A1 (en) | 2019-04-11 |
| CO2019002624A2 (es) | 2019-05-31 |
| KR20190046894A (ko) | 2019-05-07 |
| JP2019528291A (ja) | 2019-10-10 |
| US20190194179A1 (en) | 2019-06-27 |
| MX2019001978A (es) | 2019-08-01 |
| BR112019003427A2 (pt) | 2019-05-21 |
| GB201614314D0 (en) | 2016-10-05 |
| PH12019500360A1 (en) | 2019-11-11 |
| CN109923111A (zh) | 2019-06-21 |
| EA201990551A1 (ru) | 2019-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201811221XA (en) | Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201909841RA (en) | Antitumoral compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201811345TA (en) | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201807963WA (en) | Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus |